Characteristics | Normal androgen levels (number = 37) | Androgen deficiency (number = 33) | P |
---|---|---|---|
Age at study (years), mean (SD) | 55 (13) | 64 (10) | 0.005 |
Diagnosis to study (months), median (IQR) | 75 (39 to 119) | 129 (70 to 168) | 0.041 |
Last relapse to study (months), median (IQR) | 36 (19 to 67) | 49 (19 to 73) | 0.403 |
BVAS = 0, n | 37 | 33 | Â |
VDI, median (IQR) | 3 (2 to 4) | 4 (2 to 5) | 0.045 |
Cum. CY (g.), median (IQR) | 22.4 (15.5 to 39.8) | 46.6 (18.0 to 92.0) | 0.049 |
Cum. GC (g.), median (IQR) | 10.6 (6.1 to 18.4) | 21.7 (13.5 to 33.0) | 0.001 |
TT (nmol/L), mean (SD) | 17.4 (5.5) | 9.8 (1.9) | <0.001 |
FT (pmol/L), mean (SD) | 313 (103) | 193 (51) | <0.001 |
SHBG (nmol/L), mean (SD) | 43 (12) | 35 (15) | 0.029 |
Hb (mmol/L), mean (SD) | 9.0 (1.0) | 8.4 (0.9) | 0.009 |
CRP (mg/L), median (IQR) | <5 (<5 to <5) | <5 (<5 to 9) | 0.072 |
CC (ml/min), mean (SD) | 91 (27) | 89 (39) | 0.811 |
Treatment at study | Â | Â | Â |
No treatment, number | 11 | 7 | Â |
CT, number | 9 | 5 | Â |
GC (+ CT), number | 3 (1) | 7 (2) | Â |
Aza (+CT), number | 8 (6) | 2 (1) | Â |
MMF (+CT), number | 3 (3) | 2 (1) | Â |
GC and Aza (+CT), number | 1 (1) | 6 (6) | Â |
GC and MMF (+CT), number | 2 (2) | 4 (3) | Â |